Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-08
2008-01-08
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S320000, C514S415000, C548S452000, C548S465000, C548S469000, C546S184000, C546S196000
Reexamination Certificate
active
10949055
ABSTRACT:
The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.
REFERENCES:
patent: 2003/0153553 (2003-08-01), Mattei et al.
patent: WO 97/09308 (1997-03-01), None
patent: WO 00/17166 (2000-03-01), None
patent: WO 03/032992 (2003-04-01), None
Peakdale Molecular Catalog page for ID# PFC-0817, N-(1-acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide.
PCT International Search Report, dated Jan. 19, 2005, for PCT Int'l. Appln. No. PCT/US2004/031378.
Doods, Henri et al., “BIIE0246: A selective and high affinity neuropeptide Y Y2 receptor antagonist”, European Journal of Pharmacology, Amsterdam, Netherlands, vol. 384, No. 2-3, Nov. 19, 1999, pp. R3-R5.
Grouzmann Eric et al., “Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and Pharmacological evaluation of a Y2 antagonist”, Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, Maryland, US, vol. 272, No. 12, Mar. 21, 1997, pp. 7699-7706.
Jablonowski, Jill et al., “Novel non-peptidic neuropeptide Y Y2 receptor antagonists”, Bioorganic & Medicinal Chemistry Letters, 14(5), 1239-1242.
Andres, C.J. et al. Differentially Functionalized Diamines as Novel Ligands for the NPY2 Receptor. Bioorg. Med. Chem. Lett. 2003, 13(17), 2883-2885.
Baldock, P.A. Hypothalamic Y2 Receptors Regulate Bone Formation. J. Clin. Invest. 2002, 109(7), 915-921.
Batterham, R.L. et al. Gut Hormone PYY(3-36) Physiologically Inhibits Food Intake. Nature 2002, 418(6898), 650-654.
Blomqvist, A.G. and H. Herzog. Y-Receptor Subtypes—How Many More? Trends Neurosci. 1997, 20(7), 294-298.
Bonaventure, P. et al. Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4-yl]-acrylamide (JNJ-5207787), a Small Molecule Antagonist of the Neuropeptide Y Y2 Receptor. J. Pharmacol. Exp. Ther. 2004, 308(3), 1130-1137.
Clark, J.T. et al. Neuropeptide Y and Human Pancreatic Polypeptide Stimulate Feeding Behavior in Rats. Endocrinology 1984, 115(1), 427-429.
Flood, J.F. et al. Modulation of Memory Processing by Neuropeptide Y. Brain Res. 1987, 421(1-2), 280-290.
Heilig, M. et al. Antidepressant Drugs Increase the Concentration of Neuropeptide Y (NPY)-like Immunoreactivity in the Rat Brain. Eur. J. Pharmacol. 1988, 147(3), 465-467.
Heilig, M. et al. Centrally Administered Neuropeptide Y (NPY) Produces Anxiolytic-like Effects in Animal Anxiety Models. Psychopharmacology 1989, 98(4), 524-529.
Heilig, M. et al. Anxiolytic-Like Effect of Neuropeptide Y (NPY), but Not Other Peptides in an Operant Conflict Test. Regul. Pept. 1992, 41(1), 61-69.
Heilig, M. et al. Anxiolytic-Like Action of Neuropeptide Y: Mediation by Y1 Receptors in Amygdala, and Dissociation from Food Intake Effects. Neuropsychopharmacology 1993, 8(4), 357-363.
Herzog, H. Hypothalamic Y2 Receptors: Central Coordination of Energy Homeostasis and Bone Mass Regulation. Drug News Perspect. 2002, 15(8), 506-510.
Kalra, S.P. and W.R. Crowley, Neuropeptide Y: A Novel Neuroendocrine Peptide in the Control of Pituitary Hormone Secretion, and its Relation to Luteinizing Hormone. Front. Neuroendrocrinol. 1992, 13(1), 1-46.
Levine, A.S. et al. Neuropeptide Y: A Potent Inducer of Consummatory Behavior in Rats. Peptides 1984, 5(6), 1025-1029.
Morris, M.J. et al. Increases in Plasma Neuropeptide Y Concentrations During Sympathetic Activation in Man. J. Auton. Nerv. Syst. 1986, 17(2), 143-149.
Naveilhan, P. et al. Normal Feeding Behavior, Body Weight and Leptin Response Require the Neuropeptide Y Y2 Receptor. Nature Med. 1999, 5(10), 1188-1193.
Rimondini, R. et al. Suppression of Ethanol Self-administration by the Neuropeptide Y (NPY) Y2 Receptor Antagonist BIIE0246: Evidence for the Sensitization in Rats with a History of Dependence. Neurosci. Lett. 2005, 375(2), 129-133.
Stanley, B.G. and S.F. Liebowitz. Neuropeptide Y: Stimulation of Feeding and Drinking by Injection into the Paraventricular Nucleus. Life Sci. 1984, 35(26), 2635-2642.
Stanley, B.G. and S.F. Liebowitz. Neuropeptide Y Injected in the Paraventricular Hypothalamus: A Powerful Stimulant of Feeding Behavior. Proc. Nat. Acad. Sci. U.S.A. 1985, 82(11), 3940-3943.
Thiele, T.E. et al. Ethanol Consumption and Resistance are Inversely Related to Neuropeptide Y Levels. Nature 1998, 396(6709), 366-369.
Thiele, T.E. and N.E. Badia-Elder. A Role for Neuropeptide Y in Alcohol Intake Control: Evidence from Human and Animal Research. Physiol. Behav. 2003, 79(1), 95-101.
Thiele, T.E. et al. Alcoholism and Obesity: Overlapping Neuropeptide Pathways? Neuropeptides 2003, 37(6), 321-337.
Thiele, T.E. et al. Assessment of Ethanol Consumption and Water Drinking by NPY Y2 Receptor Knockout Mice. Peptides 2004, 25(6), 975-983.
Thiele, T.E. et al. A Role for Neuropeptide Y in Neurobiological Responses to Ethanol and Drugs of Abuse. Neuropeptides 2004, 38(4), 235-243.
Thorsell, A. et al. Blockade of Central Neuropeptide Y (NPY) Y2 Receptors Reduces Ethanol Self-Administration in Rats. Neurosci. Lett. 2002, 332(1), 1-4.
Widdowson, P.S. et al. Reduced Neuropeptide Y Concentrations in Suicide Brain. J. Neurochem. 1992, 59(1), 73-80.
Peakdale Molecular Catalog page for ID# PFC-0817 (N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide).
Carruthers Nicholas I.
Chai Wenying
Dax Scott L.
Jablonowski Jill A.
Li Xiaobing
Chung Susannah
Johnson & Johnson Pharmaceutical Research & Developmen
Saeed Kamal A.
LandOfFree
Non-peptidic NPY Y2 receptor inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-peptidic NPY Y2 receptor inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-peptidic NPY Y2 receptor inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3935961